Medicus Pharma’s SkinJect Data Earns KOL Validation With 80% Response in Phase 2

The latest update is out from Medicus Pharma Ltd ( (MDCX) ).

Medicus Pharma reported that key opinion leader and principal investigator Dr. Babar Rao independently validated Phase 2 data for its SkinJect microneedle-delivered doxorubicin therapy in nodular basal cell carcinoma. In the randomized, double-blind SKNJCT-003 trial, the 200 microgram dose achieved about an 80% overall response rate and 73% clinical clearance, supporting its selection as the lead regimen for further development.

Dr. Rao characterized the dataset as clinically meaningful and suitable for continued development and regulatory engagement, emphasizing its potential to delay or avoid immediate surgery for many non-melanoma skin cancer lesions. The findings suggest SkinJect could emerge as a non-surgical alternative for patients with limited access to Mohs surgery, those seeking less invasive options, and individuals with high lesion burdens, potentially strengthening Medicus Pharma’s position in dermatologic oncology.

The most recent analyst rating on (MDCX) stock is a Hold with a $0.48 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.

Spark’s Take on MDCX Stock

According to Spark, TipRanks’ AI Analyst, MDCX is a Neutral.

The score is primarily held down by weak financial performance, driven by no revenue, widening operating losses, and sharply increasing cash burn that implies ongoing external funding needs, alongside balance-sheet equity volatility. Technicals are also negative with a strong downtrend (price below all key moving averages and negative MACD), only partially tempered by oversold readings. Valuation metrics provide little support because the P/E is not meaningful and no dividend yield is available.

To see Spark’s full report on MDCX stock, click here.

More about Medicus Pharma Ltd

Medicus Pharma Ltd. is a Nasdaq-listed biotech and life sciences company focused on precision-guided, novel and potentially disruptive therapeutic assets. The company concentrates on advancing clinical development programs across multiple geographies, with an emphasis on innovative treatment platforms such as its SkinJect microneedle-delivered oncology therapy.

Average Trading Volume: 3,854,591

Technical Sentiment Signal: Sell

Current Market Cap: $17.71M

For an in-depth examination of MDCX stock, go to TipRanks’ Overview page.